abrdn plc Has $2.43 Million Stock Holdings in Codexis, Inc. (NASDAQ:CDXS)

abrdn plc trimmed its stake in shares of Codexis, Inc. (NASDAQ:CDXS) by 36.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 508,623 shares of the biotechnology company’s stock after selling 291,787 shares during the quarter. abrdn plc owned approximately 0.62% of Codexis worth $2,426,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Barclays PLC increased its holdings in shares of Codexis by 51.1% during the third quarter. Barclays PLC now owns 207,628 shares of the biotechnology company’s stock valued at $640,000 after acquiring an additional 70,255 shares in the last quarter. Geode Capital Management LLC grew its position in Codexis by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,644,039 shares of the biotechnology company’s stock valued at $5,065,000 after purchasing an additional 11,082 shares during the period. State Street Corp grew its position in Codexis by 2.7% in the 3rd quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company’s stock valued at $4,778,000 after purchasing an additional 41,480 shares during the period. Assenagon Asset Management S.A. increased its stake in Codexis by 23.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company’s stock valued at $3,399,000 after purchasing an additional 209,207 shares in the last quarter. Finally, Tallon Kerry Patrick acquired a new position in Codexis during the fourth quarter worth $2,018,000. 78.54% of the stock is owned by institutional investors and hedge funds.

Codexis Trading Down 3.2 %

Shares of NASDAQ CDXS opened at $4.18 on Tuesday. The company has a market cap of $340.17 million, a PE ratio of -4.80 and a beta of 2.12. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. The firm’s 50 day moving average price is $4.89 and its 200-day moving average price is $3.88. Codexis, Inc. has a 52-week low of $2.56 and a 52-week high of $6.08.

Analysts Set New Price Targets

A number of brokerages have issued reports on CDXS. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Codexis in a research report on Friday, November 22nd. Benchmark restated a “hold” rating on shares of Codexis in a research note on Monday, November 4th.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.